- Home
- APRE vs BIAF Comparison
APRE vs BIAF Comparison
Compare APRE & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | APRE | BIAF |
|---|---|---|
| Founded | 2006 | 2014 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3M | 5.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | APRE | BIAF |
|---|---|---|
| Price | $0.56 | $1.11 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 1 |
| Target Price | ★ $5.50 | N/A |
| AVG Volume (30 Days) | ★ 6.0M | 151.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $20.04 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.55 | $0.69 |
| 52 Week High | $3.72 | $46.53 |
Technical Indicators
Market Signals| Indicator | APRE | BIAF |
|---|---|---|
| Relative Strength Index (RSI) | 35.34 | 47.37 |
| Support Level | $0.57 | $0.69 |
| Resistance Level | $0.64 | $1.08 |
| Average True Range (ATR) | 0.16 | 0.15 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 5.24 | 62.32 |
Price Performance
Historical ComparisonAbout APRE Aprea Therapeutics Inc.
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.